Endometrial cancer risk is rising, especially among premenopausal women, with diet and lifestyle factors playing a central ...

GlaxoSmithKline Pharmaceuticals has entered the oncology segment in India, introducing Jemperli and Zejula for gynaecological ...

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies ...

GlaxoSmithKline Pharmaceuticals has launched Jemperli and Zejula in India, pioneering precision therapies for gynaecological ...

GSK India has launched Jemperli and Zejula for gynaecological cancers, marking its return to oncology a decade after ...

Bhushan Akshikar, Managing Director of GSK India, said the company is committed to making these therapies accessible through a tiered pricing strategy and a comprehensive patient support program ...

GSK enters oncology with Jemperli & Zejula for gynaecological cancers in India. Advanced therapies address unmet needs in ...

Jemperli is the first and only approved programmed death receptor-1 (PD-1) immunotherapy for the second-line treatment of ...

Pune: A teacher who rented a building to ensure 2,000 girls did not drop out of school and started distributing sanitary napkins to counter uterine ca.

GlaxoSmithKline (GSK) on Monday announced its foray into the Indian oncology market with the launch of two precision ...

GlaxoSmithKline Pharmaceuticals said it is bringing in Jemperli and Zejula to India, marking its re-entry into the cancer ...